Blood test could guide use of anti-inflammatory drug celecoxib to reduce risk of colon cancer recurrence
A data analysis from a randomized clinical trial for stage 3 colon cancer patients by investigators at Dana-Farber Brigham ...
EurekAlert!6d
Blood test could guide use of anti-inflammatory drug celecoxib to reduce risk of colon cancer recurrence
The analysis showed that patients with positive blood tests for circulating tumor DNA (ctDNA) had worse outcomes in general, but those who were treated with celecoxib, a non-steroidal anti ...
technologynetworks3d
Blood Test May Guide Anti-Inflammatory Drug Use To Reduce Colon Cancer Risk
The analysis showed that patients with positive blood tests for circulating tumor DNA (ctDNA) had worse outcomes in general, but those who were treated with celecoxib, a non-steroidal ...
EurekAlert!6d
Blood test from Alliance trial guides use of anti-inflammatory drug to lower colon cancer recurrence risk
The Alliance for Clinical Trials in Oncology today announced the results of a data analysis from a randomized phase III clinical trial involving patients with stage III colon cancer, which found that ...
Cure Today6d
ctDNA Status May Predict Disease-Free Survival With Celebrex in Colon Cancer
Celebrex improved DFS in ctDNA-positive colon cancer patients, reducing cancer recurrence and death risk by 37% compared to placebo. ctDNA status post-surgery was highly prognostic of DFS and OS, ...
Medscape2d
Perioperative Celebrex Administration for Pain Management After Total Knee Arthroplasty — A Randomized, Controlled Study
Results: Groups were comparable for age, pre-operative ROM, operation duration and intraoperative blood loss. Resting VAS pain scores improved significantly in the celecoxib group, compared with ...